| Range | 6M |
|---|---|
| First date | — |
| Last date | — |
| Open | — |
| High | — |
| Low | — |
| Close | — |
| Volume | — |
| Plotted bars | 0 |
Event records
Event records load after the price chart.
Healthcare
The Quantellect read. ELDN rose 2.53% in the Nov 18 session to $2.03. The borrow fee is 0.41%. One active firm covers the stock as of Nov 19, 2026; one active firm with a target averages $12.00 over 12 months. Descriptive summary of the data on this page, not a recommendation.
P/B 5.8× vs peer median 2.6×
RSI (14) 44.0 (overbought above 70, oversold below 30)
—
FINRA settlement Oct 30, 2026
Price $2.03 · As of Nov 18, 2026, 3:59 PM ET
| Range | 6M |
|---|---|
| First date | — |
| Last date | — |
| Open | — |
| High | — |
| Low | — |
| Close | — |
| Volume | — |
| Plotted bars | 0 |
Event records load after the price chart.
| Range | 6M |
|---|---|
| First close | — |
| Last close | — |
| High | — |
| Low | — |
| Volume | — |
ELDN · NASDAQ · USD
Split-adjusted · volume in shares
— · Notable price movement not available
— · Options flow not available
Insufficient data · Tide session Nov 18, 2026
Against 592 other US-listed Biotechnology stocks
Dot = rank among peers, low to high · tick = peer median · colour marks the top and bottom 10%
Broadly in line with peers
Not ranked: only 408 of 592 peers report it
Not ranked: only 193 of 592 peers report it
Higher than 74% of 551 peers
Profitability metrics are lower than most peers.
Not ranked: only 247 of 592 peers report it
Higher than 26% of 442 peers
Higher than 19% of 583 peers
Higher than 36% of 554 peers
Growth metrics are lower than most peers.
Higher than 32% of 592 peers
Not ranked: only 140 of 592 peers report it
Balance sheet metrics are higher than most peers.
Higher than 58% of 498 peers
Not ranked: only 117 of 592 peers report it
Returns are mixed versus peers.
Higher than 78% of 522 peers
Higher than 31% of 545 peers
Higher than 33% of 558 peers
Compared with 592 other US-listed Biotechnology stocks · fundamentals as of Nov 1, 2026 · prices as of Nov 13, 2026
Insufficient coverage
Based on 1 active firms as of Nov 19, 2026 (365-day activity window)
As of Nov 19, 2026 across 1 active firms with targets. Targets are published by third-party analysts, not by Quantellect.
Full analyst forecast →In the last 60 days: 0 insider sales and 0 purchases. Last quarter: 0 new 13F positions. No congressional trades in 90 days.
News and press releases are not available.
Data sources: exchange quotes delayed 15 minutes, FINRA short interest, SEC filings, OPRA options data and third-party analyst data. Education only. Nothing on this page is a recommendation to buy or sell a security.